Recombinant tumour necrosis factor in the local therapy of malignant pleural effusion

European Journal of Cancer Part A

Volumn 33, Issue 2, 1997, Pages 226-231

  Rauthe, G ^a   Sistermanns, J ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Krankenhaus Maria Hilf   (Germany)

Author keywords

Malignancies; Palliation; Pleural effusion; Tumour necrosis factor

Indexed keywords

RECOMBINANT TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; FEVER; HUMAN; MALE; NAUSEA; PLEURA EFFUSION; PRIORITY JOURNAL; THORAX PAIN; VOMITING;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PLEURAL EFFUSION, MALIGNANT; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030930915     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00404-2     Document Type: Article

References (18)

1. Aelony Y, King R, Boutin C. Thoracoscopic talc poudrage pleurodesis for chronic recurrent pleural effusions. Ann Intern Med 1991, 115, 778-782.
2. Bartsch HH, Pfizenmaier K, Schroeder M, Nagel GA. Intralesional application of recombinant human tumor necrosis factor alpha induces tumor regression in patients with advanced malignancies. Eur J Cancer Clin Oncol 1989, 25, 287-291.
3. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987, 47, 2986-2989.
4. Groth G, Gatzemeier U, Haussingen K, et al. Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 1991, 2, 213-215.
5. Haranaka K, Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med 1991, 51, 191-194.
6. Hartman DL, Gaither JM, Kesler KA, Mylet DM, Brown JW, Mathur PN. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993, 105, 743-747.
7. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 1985, 12, 54-75.
8. Liu CC, Liu CC, Lin CY. Changes in cell population and tumor necrosis factor, interleukin-6, and interleukin-8 in malignant pleural effusions after treatment with intrapleural tetracycline. Am Rev Respir Dis 1993, 147 (6, Pt 1), 1503-1506.
9. Maiche AG, Virkkunen P, Kontkanan T, Möykkynen K, Porkka K. Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. Am J Clin Oncol 1993, 16, 50-53.
10. Ostrowski M. An assessment of the longterm results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin. Cancer 1986, 57, 721-727.
11. Owens MW, Grimes SR. Pleural mesothelial cell response to inflammation: tumor necrosis factor-induced mitogenesis and collagen synthesis. Am J Physiol 1993, 265 (4, Pt 1), L382-L388.
12. Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions. The complementary role of talc pleurodesis and pleuroperitoneal shunting. Cancer 1995, 75, 801-805.
13. Räth U, Kaufmann M, Schmid H, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991, 27, 121-125.
14. Ruckdeschel JC. Management of malignant pleural effusions. Semin Oncol 1995, 22 (2, Suppl 3), 58-63.
15. Sistermanns J, Hoffmanns HW, Düx A. Intraperitoneal infusion of recombinant tumor necrosis factor for palliative therapy of terminally ill patients with refractory malignant ascites. Onkologie 1993, 16, 111-113.
16. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenus infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988, 80, 1039-1044.
17. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994, 120, 56-64.
18. Werner A, Mallmann P, Chronides A, Diedrich K, Wagner U, Krebs D. Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms. Zentralbl Gynäkol 1991, 113, 1313-1322.